早期应用普伐他汀对急性冠脉综合征患者临床疗效及炎症水平的影响研究

目的 观察早期应用普伐他汀对急性冠脉综合征(ACS)患者C-反应蛋白(CRP)、基质金属蛋白酶-1(MMP-1)及白介素(IL)6、10、18水平的影响.方法 将54例ACS患者根据是否早期采用普伐他汀治疗分为治疗组与非治疗组,另选取20例健康人作为对照组,观察治疗组与非治疗组的治疗总有效率；采用ELISA法测定治疗前后患者血清hs-CRP、MMP-1、IL-6、IL-10以及IL-18的水平.结果 治疗组总有效率为95.24％,显著高于非治疗组的83.33％ (P＜0.05)；与正常对照相比,ACS患者血清hs-CRP、MMP-1、IL-6、IL-18水平均显著上升(P＜0.05),而IL-10变化不明显,经过治疗后,ACS患者血清hs-CRP、MMP-1、IL-6、IL-18均较治疗前显著下降,以治疗组下降最为明显(P＜0.05),而IL-10变化则不明显(P＞0.05).结论 ACS发病与炎症反应及炎症因子失衡有关,早期使用普伐他汀治疗效果肯定,可能通过有效抑制炎症,从而起到治疗作用.

Clinical effects of applying pravastatin in treatment of acute coronary syndrome and its influence of inflammation

【Objective】 Observe effect of pravastatin in treatment of acute coronary syndrome and influence affecting CRP,MMP-1 and ILs.【Methods】 Divided 54 patients in to T group and NT group according to whether pravastatin was applied,chose 20 healthy human as control group.Total efficacy of NT group and T group was observed and compared;ELISA was applied to detect CRP,MMP-1 and ILs in serum of patients.【Results】 Total curative efficacy of T group was 95.24%,significantly higher than 83.33% of NT group(P <0.05);Compared with control,CRP,MMP-1 and IL-8,IL-6 and IL-18 in serum of ACS patients were significantly increased(P <0.05),but level of IL-10 was not changed significantly.Besides,compared with situation before treatment,CRP,MMP-1 and IL-8,IL-6 and IL-18 level in ACS patient were significantly decreased(P <0.05),especially in T group(P <0.05),except IL-10(P >0.05).【Conclusion】 Occurrence of ACS is highly related with inflammation and imbalance of inflammatory factors,applying pravastatin could effectively inhibit inflammation,presenting confirmed curative effects.